SCOTUS Cannabis Licensing Cases: Supreme Court Disputes & Rulings

Executive Summary

The Supreme Court of the United States has been asked to resolve a critical dispute over state cannabis licensing systems that could reshape how legal marijuana markets operate nationwide. The petition, filed in September 2026, challenges state regulatory frameworks that restrict the number of cannabis business licenses through merit-based or lottery systems, raising fundamental questions about due process, equal protection, and the Commerce Clause. The case arrives as 38 states have legalized medical or adult-use cannabis, creating a patchwork of licensing regimes worth over $30 billion annually. A Supreme Court ruling could force states to overhaul licensing systems that currently favor established operators, potentially opening markets to thousands of new applicants. The petition follows years of lower court battles over residency requirements, social equity programs, and arbitrary license caps that have created artificial scarcity in state-legal markets. Legal experts describe the case as the most significant cannabis federalism question since the Court declined to hear challenges to state legalization in 2016, with implications extending beyond marijuana to occupational licensing, economic liberty, and the boundaries of state police powers under the Tenth Amendment.

Why This Matters

The Supreme Court's decision on cannabis licensing will determine whether states can maintain restrictive regulatory frameworks or must open markets to broader competition, affecting billions in business value and thousands of prospective operators. The stakes extend across multiple stakeholder groups. For existing license holders, restrictive licensing systems have created valuable monopolies or oligopolies—in states like Illinois and New Jersey, dispensary licenses trade for $5 million to $15 million on secondary markets. A ruling requiring more open licensing could dilute this value overnight. For prospective applicants, particularly social equity candidates and small business owners, current systems have created insurmountable barriers. In Ohio, over 1,200 applicants competed for 73 dispensary licenses in 2017, with many qualified operators locked out by scoring systems that favored capital-rich applicants. State regulators face the prospect of dismantling carefully constructed frameworks designed to prevent federal intervention and maintain "seed-to-sale" tracking. The Cole Memorandum, rescinded in 2018 but still influential in state policy design, encouraged limited licensing to prevent diversion to illegal markets. States argue that merit-based systems ensure only well-capitalized, compliant operators enter the market, reducing the risk of federal enforcement action under the Controlled Substances Act. For patients and consumers, licensing restrictions have maintained higher prices and limited access. Economic studies show that states with capped licensing systems have retail prices 15-30% higher than states with more open licensing. In Pennsylvania, which capped dispensaries at 50 statewide initially, patients in rural counties faced drives of 60-90 minutes to reach the nearest location. Medical cannabis patients number over 3.5 million nationwide, with many dependent on consistent access to specific products for conditions ranging from epilepsy to PTSD. The case also tests the boundaries of cooperative federalism in an era when federal prohibition under the Controlled Substances Act directly conflicts with state legalization. The Department of Justice has largely deferred to state regulatory systems since the Obama administration, but a Supreme Court ruling could force DOJ to take a position on whether state licensing systems themselves violate federal law or whether they represent permissible state experimentation under the Tenth Amendment.

Background and History

Cannabis licensing disputes have evolved through three distinct eras since California became the first state to legalize medical marijuana in 1996, culminating in constitutional challenges that now reach the nation's highest court.

The Medical Marijuana Era (1996-2012)

California's Proposition 215, the Compassionate Use Act of 1996, created the first legal framework for cannabis in the modern era but included no state licensing system. The law allowed patients and caregivers to possess and cultivate marijuana with a physician's recommendation but left implementation to counties. This created a patchwork where some counties issued identification cards while others refused to participate, leading to the first wave of litigation over whether local governments could opt out of state marijuana laws. The Supreme Court's decision in Gonzales v. Raich (2005) established that federal prohibition under the Controlled Substances Act applied even to intrastate medical marijuana cultivation, but the Court did not address state licensing systems because California had none. The ruling emboldened federal prosecutors to raid dispensaries in California and other early medical states, but the Obama administration's 2009 Ogden Memorandum and 2013 Cole Memorandum established policies of non-interference with state-legal operations that complied with robust regulatory frameworks. By 2012, 18 states had legalized medical cannabis, with widely varying approaches. New Mexico, Rhode Island, and New Jersey created closed-loop systems with limited licenses for vertically integrated operators. Michigan and Maine allowed relatively open licensing with lower barriers to entry. Colorado and Washington prepared to implement the first adult-use systems following voter approval in November 2012, forcing regulators to design licensing frameworks from scratch.

Adult-Use Legalization and the Rise of Limited Licensing (2012-2020)

Colorado and Washington launched adult-use sales in 2014 with fundamentally different licensing philosophies. Colorado adopted a relatively open system, converting existing medical dispensaries to adult-use and accepting new applications on a rolling basis, subject to local approval. By 2016, Colorado had issued over 500 retail licenses. Washington implemented a lottery system capped at 334 retail licenses statewide, with geographic distribution requirements. The lottery drew over 2,800 applications, and rejected applicants immediately filed lawsuits alleging the random selection process violated due process and equal protection. In Weed v. Washington State Liquor and Cannabis Board (2016), the Washington Supreme Court rejected constitutional challenges to the lottery system, holding that the state had a rational basis for limiting licenses to prevent federal intervention and that applicants had no protected property interest in a license before it was granted. The ruling established a framework that other states would follow, but it left open questions about whether merit-based systems with subjective scoring criteria would survive scrutiny. Illinois became the test case for social equity licensing when it legalized adult-use cannabis in 2019 with a system awarding bonus points to applicants from communities disproportionately harmed by the War on Drugs. The Illinois Department of Financial and Professional Regulation received over 4,000 applications for 75 dispensary licenses in 2020, with scoring based on business plans, capital, and social equity status. The application process collapsed into chaos when a lottery to break tied scores resulted in 21 perfect-score applications, leading to lawsuits from rejected applicants who alleged the scoring was arbitrary and that politically connected applicants received improper assistance. In Rowe v. Illinois Department of Financial and Professional Regulation (2022), the Illinois Seventh Circuit Court of Appeals upheld the licensing system against equal protection and due process challenges, ruling that the state's interest in promoting social equity and preventing market saturation provided a rational basis for the scoring system. However, the court noted that "more arbitrary or capricious application of scoring criteria might present a closer constitutional question."

The Current Wave of Constitutional Challenges (2020-2026)

Between 2020 and 2026, rejected cannabis license applicants filed over 150 federal and state lawsuits challenging licensing systems, with cases reaching state supreme courts in New York, New Jersey, Ohio, Michigan, and Maryland. The legal theories evolved beyond due process and equal protection to include Commerce Clause challenges to residency requirements, First Amendment challenges to restrictions on advertising and branding, and takings claims when states revoked or failed to renew licenses. New York's licensing system became the most litigated in the nation. The state's 2021 Marijuana Regulation and Taxation Act prioritized licenses for individuals with prior cannabis convictions, women and minority-owned businesses, and distressed farmers. When the Office of Cannabis Management began issuing Conditional Adult-Use Retail Dispensary licenses in 2022, out-of-state operators filed suit alleging the residency requirements violated the dormant Commerce Clause. In Variscite NY One v. Tremaine (2023), a federal district court issued a preliminary injunction halting New York's licensing program, finding that the residency requirement likely discriminated against interstate commerce. The Second Circuit stayed the injunction pending appeal, but the case highlighted the tension between state social equity goals and constitutional limits on economic protectionism. Ohio's licensing system faced challenges on different grounds. The state's 2023 adult-use legalization measure, Issue 2, directed the Division of Cannabis Control to issue certificates of operation through a competitive application process. When the Division announced it would cap initial licenses at 150 dispensaries and 50 cultivators statewide, rejected applicants filed suit alleging the arbitrary cap violated substantive due process by restricting economic liberty without a legitimate state interest. In Green Horizons v. Ohio Division of Cannabis Control (2025), the Ohio Supreme Court rejected the challenge, holding that the state's interest in preventing federal intervention and maintaining effective regulation provided a rational basis for license caps. The petition now before the U.S. Supreme Court consolidates issues from multiple circuit court decisions, asking the Court to resolve whether state cannabis licensing systems that impose arbitrary numerical caps, use subjective merit-based scoring, or include residency requirements violate the Due Process Clause, Equal Protection Clause, or Commerce Clause of the U.S. Constitution.

Key Players

Petitioners and Rejected Applicants

The lead petitioner in the consolidated case is a coalition of rejected license applicants from six states, represented by the Institute for Justice, a libertarian public interest law firm that has challenged occupational licensing restrictions nationwide. The petitioners include social equity applicants who scored below cutoffs despite meeting statutory criteria, out-of-state operators blocked by residency requirements, and small business owners who lost lotteries to applicants with identical qualifications. Their core argument is that state licensing systems create arbitrary barriers to lawful economic activity without adequate procedural protections or substantive justification.

State Regulators and Attorneys General

Twenty-three state attorneys general filed amicus briefs opposing Supreme Court review, arguing that cannabis licensing falls within the traditional police powers reserved to states under the Tenth Amendment. The National Cannabis Industry Regulators Association, representing state regulatory agencies, contends that limited licensing systems are necessary to prevent diversion to illegal markets, ensure product safety through rigorous oversight of a manageable number of operators, and reduce the risk of federal enforcement action. States emphasize that the Cole Memorandum, though rescinded, identified "preventing revenue from the sale of marijuana from going to criminal enterprises, gangs, and cartels" as a federal enforcement priority that limited licensing helps address.

Existing License Holders and Industry Associations

The National Cannabis Industry Association and several multi-state operators filed amicus briefs with conflicting positions. Established operators with licenses in multiple states generally oppose Supreme Court intervention, arguing that regulatory stability is essential for the $30 billion legal cannabis industry and that forcing states to issue unlimited licenses would create market chaos, price collapse, and increased risk of diversion. However, the National Cannabis Roundtable, representing smaller operators and ancillary businesses, filed a brief supporting the petitioners, arguing that artificial scarcity benefits large MSOs at the expense of small businesses and social equity applicants.

Civil Rights and Drug Policy Reform Organizations

The Drug Policy Alliance, ACLU, and Minority Cannabis Business Association filed a joint amicus brief taking a nuanced position: supporting challenges to arbitrary and discriminatory licensing practices while defending social equity programs and state authority to regulate cannabis markets. These organizations argue that the real constitutional problem is not limited licensing per se, but the failure of states to design systems that genuinely advance stated goals of repairing harms from prohibition. They point to data showing that in Illinois, despite social equity provisions, fewer than 20% of licenses went to Black or Latino applicants in communities most impacted by the War on Drugs.

Federal Government

The Department of Justice filed a brief opposing Supreme Court review, arguing that the case is not ripe for adjudication because cannabis remains a Schedule I controlled substance under federal law, and state licensing systems exist in tension with the Controlled Substances Act. DOJ contends that the Court should not resolve state regulatory questions about a substance that federal law prohibits entirely. However, the brief notably does not argue that state licensing systems themselves violate federal law, reflecting the department's continued policy of non-interference with state-legal cannabis operations.

Legal and Regulatory Framework

Cannabis licensing disputes operate at the intersection of federal prohibition, state legalization, and constitutional limits on state regulatory authority, creating a complex legal framework without clear precedent.

Federal Law: The Controlled Substances Act

Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812, meaning federal law prohibits its manufacture, distribution, and possession. The CSA contains no exception for state-legal cannabis operations, and the Supreme Court held in Gonzales v. Raich that Congress's Commerce Clause authority extends to intrastate cannabis cultivation. However, Congress has annually passed appropriations riders prohibiting DOJ from using funds to interfere with state medical cannabis programs, and the department has maintained policies of non-interference with state-legal operations since 2009. The CSA does not preempt state legalization or licensing systems. States are not required to criminalize conduct that federal law prohibits, and state licensing systems do not authorize conduct under federal law—they merely establish that state law enforcement will not prosecute compliant operators. This creates a legal gray area where state-licensed cannabis businesses operate in violation of federal law but face minimal risk of federal prosecution.

Constitutional Limits on State Licensing

The Due Process Clause of the Fourteenth Amendment requires that government deprivations of life, liberty, or property follow fair procedures (procedural due process) and that regulations have a rational relationship to a legitimate government interest (substantive due process). In the occupational licensing context, the Supreme Court has held that states have broad authority to regulate professions and businesses, but regulations cannot be arbitrary or irrational. In Schware v. Board of Bar Examiners (1957), the Court struck down a state bar application denial based on the applicant's past Communist Party membership, holding that the denial bore no rational connection to fitness to practice law. Cannabis license applicants argue that caps on license numbers, subjective scoring systems, and lottery-based selection are arbitrary deprivations of economic liberty. States respond that preventing federal intervention, ensuring effective regulation, and limiting market saturation are legitimate interests that justify licensing restrictions. The Equal Protection Clause requires that similarly situated individuals be treated alike. Under rational basis review, which applies to economic regulations, states need only show that a classification is rationally related to a legitimate government interest. However, if a licensing system discriminates based on a suspect classification like race, or if it burdens a fundamental right, courts apply heightened scrutiny. Social equity programs that award preference points based on race or ethnicity face potential equal protection challenges, though courts have generally upheld such programs when they serve compelling interests in remedying past discrimination and are narrowly tailored. The Commerce Clause, Article I, Section 8, grants Congress authority to regulate interstate commerce, and the "dormant" Commerce Clause doctrine prohibits states from discriminating against or unduly burdening interstate commerce. Residency requirements for cannabis licenses face dormant Commerce Clause challenges because they explicitly favor in-state residents over out-of-state applicants. In Granholm v. Heald (2005), the Supreme Court struck down state laws that allowed in-state wineries to ship directly to consumers but prohibited out-of-state wineries from doing so, holding that the discrimination against interstate commerce was not justified by the state's interest in preventing underage drinking. Cannabis licensing residency requirements present similar issues, though states argue that the continuing federal prohibition of cannabis distinguishes the cases.

State Statutory Frameworks

State cannabis licensing statutes vary widely but generally include several common elements: application requirements (background checks, financial disclosures, business plans), eligibility criteria (residency, capital requirements, absence of disqualifying criminal convictions), license types (cultivation, processing, testing, retail, with varying vertical integration rules), numerical caps or competitive processes, and ongoing compliance obligations (inventory tracking, testing, security, reporting). Illinois's Cannabis Regulation and Tax Act exemplifies a detailed statutory framework. The law directs the Department of Financial and Professional Regulation to issue licenses through a competitive point-based system, with points awarded for business plan quality (maximum 30 points), capital and financial plan (20 points), diversity plan (10 points), social equity status (50 bonus points), and labor and employment practices (2 points). Applicants must demonstrate $400,000 in liquid assets and $750,000 in total assets. The law caps initial dispensary licenses at 75 for social equity applicants and 110 for general applicants, with geographic distribution requirements. Michigan's Marihuana Regulatory Agency operates under a statute that does not cap license numbers but requires local municipal approval, creating a de facto limit based on local opt-in decisions. Approximately 1,600 municipalities in Michigan have opted out of allowing cannabis businesses, while 300 have opted in, creating geographic concentration in permissive jurisdictions.

State-by-State Breakdown of Licensing Systems

The 38 states with legal cannabis markets employ licensing systems ranging from open application processes to strict numerical caps, with significant variation in social equity provisions, residency requirements, and vertical integration rules.

California

California operates a dual-license system requiring both state approval from the Department of Cannabis Control and local authorization from the city or county where the business will operate. The state does not cap license numbers, but local control creates significant variation—Los Angeles has issued over 400 retail licenses, while San Francisco has fewer than 50. Social equity programs in Los Angeles, Oakland, and San Francisco provide fee waivers, technical assistance, and priority application processing for equity applicants, defined as individuals with prior cannabis convictions or residence in disproportionately impacted areas. As of September 2026, California has issued over 3,000 active retail licenses statewide, the most of any state.

Colorado

Colorado's Marijuana Enforcement Division issues licenses without numerical caps, subject to local approval. The state has issued over 600 retail licenses since 2014, with concentration in Denver and resort communities. Colorado does not have formal social equity provisions but allows local jurisdictions to create their own programs. Residency requirements were eliminated in 2021 following litigation. The state requires separate licenses for medical and adult-use sales, though businesses can hold both.

Illinois

Illinois implemented one of the most restrictive licensing systems, initially capping dispensaries at 185 statewide with 75 reserved for social equity applicants. The point-based scoring system awards up to 250 points, with 50 bonus points for social equity status (residence in a disproportionately impacted area, prior cannabis arrest, or employment of 10+ residents of such areas). The 2020 application round received over 4,000 applications for 75 licenses, with scoring disputes leading to extensive litigation. A 2022 supplemental lottery awarded 185 additional licenses. As of September 2026, Illinois has 185 operational dispensaries, serving a population of 12.6 million—a ratio of one dispensary per 68,000 residents, compared to Colorado's one per 9,000.

Michigan

Michigan does not cap state-level licenses but requires local authorization, creating a patchwork of availability. The state has issued over 1,000 retail licenses, with concentration in Detroit, Ann Arbor, and other permissive municipalities. Social equity provisions include fee reductions and priority processing for applicants with prior cannabis convictions or residence in communities with high arrest rates. Michigan allows vertical integration, and several MSOs operate cultivation, processing, and retail under common ownership.

New Jersey

New Jersey's Cannabis Regulatory Commission initially issued 13 medical dispensary licenses in 2018 through a competitive application process, then awarded those operators first priority for adult-use licenses when sales began in 2022. The state has since issued over 100 additional retail licenses through rolling application windows, with priority for social equity applicants (prior cannabis conviction, residence in "impact zones" with high arrest rates, or attendance at a historically Black college or university). Residency requirements mandate that at least 51% of ownership be New Jersey residents for the first two years of operation. As of September 2026, New Jersey has 87 operational dispensaries.

New York

New York's Office of Cannabis Management prioritized Conditional Adult-Use Retail Dispensary licenses for individuals with prior cannabis convictions, awarding the first 150 licenses in 2022-2023. The program faced immediate legal challenges over residency requirements and allegations of favoritism, leading to a federal court injunction that temporarily halted licensing. The state has since issued over 200 licenses but faces ongoing litigation. New York prohibits vertical integration for the first three years, requiring separate licenses for cultivation, processing, distribution, and retail.

Ohio

Ohio's Division of Cannabis Control issued 73 dispensary licenses in 2017 through a competitive scoring process, with applications evaluated on business plan, capital, security, and other factors. The state received over 1,200 applications, and rejected applicants filed numerous lawsuits alleging scoring irregularities. Following adult-use legalization in 2023, Ohio announced plans to issue 150 additional dispensary licenses and 50 cultivator licenses through a new competitive process. The state requires Ohio residency for at least two years for all owners and investors.

Pennsylvania

Pennsylvania's medical marijuana program initially capped dispensaries at 50 statewide, later expanded to 75, then to unlimited licenses in 2022. The state uses a competitive application process with scoring based on diversity, capital, business plan, and community impact. Pennsylvania does not have adult-use legalization as of September 2026. The state prohibits vertical integration, requiring separate grower/processor and dispensary licenses.

Washington

Washington capped retail licenses at 556 statewide with geographic allocation by county based on population. Initial licenses in 2014 were awarded by lottery, with subsequent licenses issued through merit-based applications when existing licenses are relinquished. The state does not have formal social equity provisions. Washington requires a 6-month residency for all owners and investors. As of September 2026, all 556 licenses have been issued, and new applicants must wait for existing licenses to become available.

Market and Business Implications

Cannabis licensing restrictions have created artificial scarcity that inflates license values, limits competition, and maintains higher consumer prices, with significant implications for MSOs, investors, and market structure.

License Valuation and Secondary Markets

In states with strict license caps, dispensary licenses trade on secondary markets for $3 million to $15 million, depending on location and market size. Illinois dispensary licenses have sold for $8-12 million in the Chicago area, while New Jersey licenses command $5-8 million. These valuations reflect the present value of future profits in markets with limited competition. A Supreme Court ruling requiring more open licensing could eliminate this scarcity premium overnight, destroying billions in enterprise value for existing operators. Cultivation licenses show similar patterns. In Ohio, cultivator licenses have traded for $15-25 million, reflecting the limited number of suppliers (50 statewide) serving a medical market of over 200,000 registered patients. In contrast, Oklahoma's open licensing system, which issued over 2,000 cultivation licenses, saw wholesale cannabis prices collapse from $2,500 per pound in 2019 to under $1,000 per pound by 2022, with many cultivators operating at a loss.

MSO Consolidation and Market Concentration

Limited licensing systems have accelerated consolidation among multi-state operators. Companies like Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have assembled portfolios of dozens of licenses across multiple states, with combined market capitalizations exceeding $10 billion. These MSOs benefit from barriers to entry that prevent new competition and from economies of scale in cultivation, processing, and distribution. In Illinois, the top five MSOs control over 60% of retail sales, despite social equity provisions intended to promote diverse ownership. Critics argue that capital requirements ($750,000 in assets for a dispensary application), complex regulatory compliance, and the difficulty of securing banking and insurance create structural advantages for well-funded operators. Social equity applicants who win licenses often partner with or sell to MSOs that provide capital and operational expertise.

Impact on Wholesale and Retail Pricing

Economic analysis shows that states with capped licensing have retail prices 15-30% higher than states with open licensing, controlling for taxes and market maturity. In Illinois, adult-use cannabis retails for $50-70 per eighth ounce ($400-560 per ounce) including taxes, compared to $30-45 per eighth in Michigan ($240-360 per ounce). The price differential reflects both Illinois's higher tax rates and the limited retail competition—one dispensary per 68,000 residents versus one per 10,000 in Michigan. Wholesale prices show even starker differences. In capped markets like Ohio and Pennsylvania, cultivators sell wholesale flower for $2,500-3,500 per pound. In open markets like Oklahoma and Oregon, wholesale prices have fallen to $800-1,200 per pound, with some distressed sales below $500 per pound. The wholesale price collapse in open markets has driven many small cultivators out of business but has benefited consumers and processors.

Capital Markets and Investment

Cannabis remains a high-risk investment due to federal prohibition, limited banking access, and regulatory uncertainty. The potential for Supreme Court intervention in state licensing adds another layer of risk. Institutional investors have largely avoided the sector, with cannabis companies trading on Canadian exchanges or U.S. over-the-counter markets rather than the NYSE or NASDAQ. Total capital raised by U.S. cannabis companies reached $12 billion between 2019 and 2025, but funding has declined as investors reassess growth prospects in maturing markets. A Supreme Court ruling requiring open licensing could have contradictory effects on capital markets. Existing MSOs would likely see share price declines as investors price in increased competition and margin compression. However, the overall market could expand as new entrants drive geographic coverage, product innovation, and consumer adoption. Ancillary businesses—software, testing labs, security, packaging—could benefit from a larger number of licensed operators.

What Experts Say

Legal scholars, industry analysts, and policy advocates offer sharply divergent views on whether the Supreme Court should intervene in state cannabis licensing and what the consequences would be. Robert Mikos, professor at Vanderbilt Law School and author of "Marijuana Law, Policy, and Authority," argues that the Court should decline to hear the case because cannabis licensing disputes are not ripe for federal adjudication while cannabis remains federally illegal. According to Mikos, the Court has historically avoided resolving state regulatory questions about conduct that federal law prohibits, and intervening now would force the Court to take a position on the legitimacy of state legalization itself. Mikos contends that Congress should resolve the conflict between federal prohibition and state legalization before courts address licensing questions. Sam Kamin, professor at the University of Denver Sturm College of Law, takes a different view, arguing that the Court should grant review to establish clear constitutional limits on state licensing systems. According to Kamin, the current patchwork of state licensing regimes includes systems that are genuinely arbitrary and that burden economic liberty without adequate justification. Kamin points to lottery-based systems as particularly problematic, arguing that awarding valuable economic rights by random chance fails rational basis review when states could use merit-based criteria or open licensing. The Institute for Justice, representing the petitioners, argues that cannabis licensing restrictions are part of a broader pattern of excessive occupational licensing that burdens economic opportunity nationwide. According to IJ, one in four American workers now requires a government license to work, up from one in 20 in the 1950s, and many licensing requirements lack empirical justification. IJ contends that cannabis licensing caps are particularly arbitrary because states have not demonstrated that limiting the number of operators improves public health or safety outcomes compared to open licensing with ongoing compliance requirements. Industry analysts at Cowen & Company project that a Supreme Court ruling requiring open licensing would reduce cannabis retail prices by 20-35% over three years as new entrants increase competition. According to Cowen, this would accelerate the shift of consumer spending from illegal markets to legal markets, potentially growing the total legal market from $30 billion to $45 billion by 2030. However, Cowen projects that existing MSOs would see revenue declines of 10-15% and EBITDA margin compression of 5-8 percentage points as they face new competition. The Drug Policy Alliance emphasizes that licensing disputes must be evaluated in the context of the War on Drugs and its disproportionate impact on communities of color. According to DPA, Black Americans are 3.6 times more likely than white Americans to be arrested for cannabis possession despite similar usage rates, and cannabis legalization should prioritize repairing this harm through social equity licensing. DPA argues that the Supreme Court should strike down arbitrary licensing practices while preserving state authority to implement social equity programs, residency requirements, and other measures that advance racial and economic justice. Beau Kilmer, co-director of the RAND Drug Policy Research Center, points to data from Washington and Colorado showing that limited licensing in Washington did not prevent diversion to illegal markets or improve public health outcomes compared to Colorado's more open system. According to Kilmer, the empirical evidence does not support claims that license caps are necessary for effective regulation. Kilmer argues that states should focus on rigorous compliance monitoring, product testing, and enforcement against unlicensed operators rather than limiting the number of legal operators.

What's Next

The Supreme Court will decide whether to grant certiorari in the consolidated cannabis licensing case during the October 2026 term, with a decision on the petition expected by January 2027. If the Court grants review, oral arguments would likely occur in spring 2027, with a decision by June 2027. The Court receives over 7,000 petitions per year and grants review in fewer than 100 cases, typically selecting cases that resolve circuit splits or address questions of national importance. The cannabis licensing petition presents both characteristics—circuit courts have reached different conclusions on the constitutionality of residency requirements and license caps, and the question affects 38 states and a $30 billion industry. If the Court declines review, state licensing systems would continue to operate under current legal frameworks, with challenges proceeding through state courts and lower federal courts. This outcome would maintain the status quo but leave unresolved conflicts between circuits and continued uncertainty for operators and investors. If the Court grants review and rules in favor of the petitioners, states would face several possible remedies depending on the scope of the decision: A narrow ruling could strike down specific practices—such as lottery-based selection or residency requirements—while preserving state authority to cap license numbers and use merit-based criteria. This would require states to redesign licensing systems but would not mandate open licensing. A broad ruling could hold that arbitrary numerical caps on licenses violate substantive due process, requiring states to justify specific license limits based on empirical evidence of public health or safety benefits. This would force states to either eliminate caps or conduct studies demonstrating that limited licensing improves outcomes compared to open licensing with compliance requirements. The most expansive ruling would hold that cannabis licensing restrictions constitute economic protectionism that violates the dormant Commerce Clause or that they burden economic liberty without adequate justification under heightened scrutiny. This outcome would effectively require open licensing systems, though states could still impose background checks, capital requirements, and ongoing compliance obligations. Parallel developments will influence the landscape regardless of the Supreme Court's decision. The Drug Enforcement Administration's proposed rescheduling of cannabis from Schedule I to Schedule III, currently in notice-and-comment rulemaking, would not legalize cannabis under federal law but would eliminate the 280E tax penalty that prohibits cannabis businesses from deducting ordinary business expenses. Rescheduling could reduce federal-state tensions and make courts more willing to address state licensing questions. Congressional legislation remains a possibility, though prospects are uncertain. The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has passed the House multiple times but stalled in the Senate. More comprehensive legislation like the Cannabis Administration and Opportunity Act would deschedule cannabis entirely and establish federal regulatory oversight, potentially preempting state licensing systems or establishing minimum standards. State legislatures continue to revise licensing systems in response to litigation and market developments. New York, Illinois, and New Jersey have all amended licensing statutes in the past two years to address court challenges, expand license numbers, or modify social equity provisions. These revisions could moot some claims in the Supreme Court petition, though the underlying constitutional questions would remain.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• Gonzales v.